Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | MicrobiomeTrials
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-12-29Est. Completion: 2027-04
Enrollment target: 632 participants
Locations
Site 102002, Banja Luka, Bosnia and Herzegovina
Site 102001, Sarajevo, Bosnia and Herzegovina
Site 102003, Zenica, Bosnia and Herzegovina
Site 103009, Barretos, Brazil
Site 103007, Belo Horizonte, Brazil
Site 103008, Belo Horizonte, Brazil
Site 103002, Bento Gonçalves, Brazil
Site 103014, Blumenau, Brazil
Site 103012, Caxias do Sul, Brazil
Site 103004, Ijuí, Brazil
Site 103013, Jaú, Brazil
Site 103015, Lajeado, Brazil
Site 103010, Natal, Brazil
Site 103001, Porto Alegre, Brazil
Site 103011, Ribeirão Preto, Brazil
Site 103018, Rio de Janeiro, Brazil
Site 103017, Santa Cruz do Sul, Brazil
Site 103005, São Caetano do Sul, Brazil
Site 103016, São Paulo, Brazil
Site 103006, Sorocaba, Brazil
Site 104002, Independencia, Chile
Site 104004, La Florida, Chile
Other microbiome trials you might be interested in